Predict your next investment

Corporation
INDUSTRIAL | Basic Materials / Specialty Chemicals
elevance.com

See what CB Insights has to offer

Executives

8

Board of Directors

4

Elevance Renewable Sciences Board of Directors

4 Board of directors

Elevance Renewable Sciences has 4 board of directors, including Geoffrey Duyk.

Name

Firm

Work History

Other Seats

Geoffrey Duyk

Prior to joining TPG Biotech in 2004, Geoffrey Duyk served on the board of directors and was president of research and development at Exelixis where he led a 550+ person group focused on the discovery and development of small molecule therapeutics. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals. As vice president of genomics at Millennium, Duyk was responsible for building and leading the informatics, automation, DNA sequencing and genotyping groups as well as the mouse and human genetics group. Prior to his tenure at Millennium, Dr. Duyk was an assistant professor at Harvard Medical School (HMS) in the Department of Genetics and assistant investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a co-principal investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the Human Genome Project. Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute. Dr. Duyk serves on the board of directors of Replidyne, Macrogenics, Aerie, FoldRx, Amyris, Galleon, Moksha8, ShangPharma, Agria, Renewco and JCR. He is a council member of the National Human Genome Research Institute at the National Institutes of Health. He also serves on the scientific advisory boards of the NHGRI DNA Sequencing Advisory Panel, chair of the KOMP (Global Mouse TKO project), ESC (Expressed Sequenced Consortium), co-chair advisory panel Cancer Genome Anatomy Project, Program in Genomics Applications (NHBLI); the Bioethics Advisory Group at Case Western Reserve University; the Spinal Muscular Atrophy Foundation; WIL Laboratories; VLST; and FoldRx. Dr. Duyk is a former member of the board of directors of Avidia, recently sold to Amgen.

Elevance Renewable Sciences

Patrick Mccroskey

Elevance Renewable Sciences

Robert Shapiro

Bob Shapiro is the co-founder and managing director of Sandbox Industries, a venture capital firm that partners with Cultivian Sandbox for investments in food and agriculture technology. He is the former chairman of Pharmacia, chairman and CEO of Monsanto, and chairman and CEO of The NutraSweet Company. Bob previously served as vice president and general counsel of G.D. Searle & Company and General Instrument Corporation. Prior to this, he practiced law in New York City and was a professor of law at Northeastern University in Boston and the University of Wisconsin-Madison. He is a Fellow of the American Academy of Arts and Sciences.

Elevance Renewable Sciences

William Mcglashan

Elevance Renewable Sciences

Name

Geoffrey Duyk

Patrick Mccroskey

Robert Shapiro

William Mcglashan

Firm

Work History

Prior to joining TPG Biotech in 2004, Geoffrey Duyk served on the board of directors and was president of research and development at Exelixis where he led a 550+ person group focused on the discovery and development of small molecule therapeutics. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals. As vice president of genomics at Millennium, Duyk was responsible for building and leading the informatics, automation, DNA sequencing and genotyping groups as well as the mouse and human genetics group. Prior to his tenure at Millennium, Dr. Duyk was an assistant professor at Harvard Medical School (HMS) in the Department of Genetics and assistant investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a co-principal investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused on the planning and execution of the Human Genome Project. Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from the Howard Hughes Medical Institute. Dr. Duyk serves on the board of directors of Replidyne, Macrogenics, Aerie, FoldRx, Amyris, Galleon, Moksha8, ShangPharma, Agria, Renewco and JCR. He is a council member of the National Human Genome Research Institute at the National Institutes of Health. He also serves on the scientific advisory boards of the NHGRI DNA Sequencing Advisory Panel, chair of the KOMP (Global Mouse TKO project), ESC (Expressed Sequenced Consortium), co-chair advisory panel Cancer Genome Anatomy Project, Program in Genomics Applications (NHBLI); the Bioethics Advisory Group at Case Western Reserve University; the Spinal Muscular Atrophy Foundation; WIL Laboratories; VLST; and FoldRx. Dr. Duyk is a former member of the board of directors of Avidia, recently sold to Amgen.

Bob Shapiro is the co-founder and managing director of Sandbox Industries, a venture capital firm that partners with Cultivian Sandbox for investments in food and agriculture technology. He is the former chairman of Pharmacia, chairman and CEO of Monsanto, and chairman and CEO of The NutraSweet Company. Bob previously served as vice president and general counsel of G.D. Searle & Company and General Instrument Corporation. Prior to this, he practiced law in New York City and was a professor of law at Northeastern University in Boston and the University of Wisconsin-Madison. He is a Fellow of the American Academy of Arts and Sciences.

Other Seats

Elevance Renewable Sciences

Elevance Renewable Sciences

Elevance Renewable Sciences

Elevance Renewable Sciences

Elevance Renewable Sciences Management Team

8 Team Members

Elevance Renewable Sciences has 8 executives. Elevance Renewable Sciences's former Chief Executive Officer is K'Lynne Johnson.

Name

Work History

Title

Status

K'Lynne Johnson

Chief Executive Officer

Former

Patrick Kelly

Chief Financial Officer

Former

David H Kelsey

Chief Financial Officer

Former

David Kelsey

Sealed Air, GE Capital, and General Electric

Chief Financial Officer

Former

Mel Luetkens

INEOS, and BP

Chief Operating Officer

Former

Name

K'Lynne Johnson

Patrick Kelly

David H Kelsey

David Kelsey

Mel Luetkens

Work History

Sealed Air, GE Capital, and General Electric

INEOS, and BP

Title

Chief Executive Officer

Chief Financial Officer

Chief Financial Officer

Chief Financial Officer

Chief Operating Officer

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.